$240M+ in Deals and 1 New Approval Mark CGT Momentum Surge at ASGCT

Published on Spencer Knight via LinkedIn

A packed week at ASGCT brought a wave of new CGT developments totaling over $240 million in funding and one new regulatory approval. Highlights include:

• Sarepta received Japanese approval for ELEVIDYS in Duchenne muscular dystrophy

• Abeona received a $155M Priority Review Voucher

• PolTREG gained EMA pediatric plan approval for T1D and expanded MS/ALS studies

• Cabaletta Bio received RMAT for res-cel in myasthenia gravis

• BrainChild Bio got RMAT for BT-H3 CAR-T in pediatric brain tumors

• Stylus Medicine raised $85M to launch in vivo gene editing company

• Somite AI raised $47M for DeltaStem AI-driven cell manufacturing

• AGC + Quell launched a vector supply partnership for Treg therapies

Spencer Knight notes this is the strongest CGT activity week in months, signaling renewed industry confidence and expanding regulatory progress.

Read the full post on LinkedIn:

👉 Spencer Knight: Momentum Returns to CGT at ASGCT

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.